A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington diseaseAndrew McGarry, Lauren Seeberger, Ramon L. Rodriguez et al.|Neurology|2016Cited by 137
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Karl Kieburtz, Shane Rosanbalm et al.|The Lancet Neurology|2023Cited by 128
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Hope Heller, Andrew McGarry et al.|The Lancet Neurology|2018Cited by 108
Pharmacologic approaches to the treatment of Huntington's diseaseCharles S. Venuto, Karl Kieburtz, Andrew McGarry et al.|Movement Disorders|2011Cited by 84
Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington’s disease for participants of varying functional disability: a pilot studyAndrew McGarry, Ruin Moaddel, John Gaughan et al.|Scientific Reports|2020Cited by 38